Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 21

1.

Tamoxifen Resistance: Emerging Molecular Targets.

Rondón-Lagos M, Villegas VE, Rangel N, Sánchez MC, Zaphiropoulos PG.

Int J Mol Sci. 2016 Aug 19;17(8). pii: E1357. doi: 10.3390/ijms17081357. Review.

2.

Optimal approach in early breast cancer: Adjuvant and neoadjuvant treatment.

Ribeiro J, Sousa B, Cardoso F.

EJC Suppl. 2013 Sep;11(2):3-22. doi: 10.1016/j.ejcsup.2013.07.029. Review. No abstract available.

3.

Downregulation of ER-α36 expression sensitizes HER2 overexpressing breast cancer cells to tamoxifen.

Yin L, Pan X, Zhang XT, Guo YM, Wang ZY, Gong Y, Wang M.

Am J Cancer Res. 2015 Jan 15;5(2):530-44.

4.

Accumulation of p53 is prognostic for aromatase inhibitor resistance in early-stage postmenopausal patients with ER-positive breast cancer.

Jia XQ, Hong Q, Cheng JY, Li JW, Wang YJ, Mo M, Shao ZM, Shen ZZ, Liu GY.

Onco Targets Ther. 2015 Mar 3;8:549-55. doi: 10.2147/OTT.S76879.

5.

Therapeutic advances in BIG3-PHB2 inhibition targeting the crosstalk between estrogen and growth factors in breast cancer.

Yoshimaru T, Komatsu M, Miyoshi Y, Honda J, Sasa M, Katagiri T.

Cancer Sci. 2015 May;106(5):550-8. doi: 10.1111/cas.12654.

6.

Disruption of the ER-α36-EGFR/HER2 positive regulatory loops restores tamoxifen sensitivity in tamoxifen resistance breast cancer cells.

Yin L, Zhang XT, Bian XW, Guo YM, Wang ZY.

PLoS One. 2014 Sep 9;9(9):e107369. doi: 10.1371/journal.pone.0107369.

7.

Clinical utility of the combination of lapatinib and letrozole in the management of hormone receptor-positive and HER2-positive advanced breast cancer.

Merriam P, Sikov WM.

Breast Cancer (Dove Med Press). 2011 Oct 26;3:139-50. doi: 10.2147/BCTT.S12150. Review.

8.

Survival benefit of tamoxifen in estrogen receptor-negative and progesterone receptor-positive low grade breast cancer patients.

Yang LH, Tseng HS, Lin C, Chen LS, Chen ST, Kuo SJ, Chen DR.

J Breast Cancer. 2012 Sep;15(3):288-95. doi: 10.4048/jbc.2012.15.3.288.

9.

Moderate immunohistochemical expression of HER-2 (2+) without HER-2 gene amplification is a negative prognostic factor in early breast cancer.

Rossi V, Sarotto I, Maggiorotto F, Berchialla P, Kubatzki F, Tomasi N, Redana S, Martinello R, Valabrega G, Aglietta M, Ponzone R, Montemurro F.

Oncologist. 2012;17(11):1418-25. doi: 10.1634/theoncologist.2012-0194.

10.

HER2 evaluation and its impact on breast cancer treatment decisions.

Goddard KA, Weinmann S, Richert-Boe K, Chen C, Bulkley J, Wax C.

Public Health Genomics. 2012;15(1):1-10. doi: 10.1159/000325746.

11.

Estrogen receptor β represses Akt signaling in breast cancer cells via downregulation of HER2/HER3 and upregulation of PTEN: implications for tamoxifen sensitivity.

Lindberg K, Helguero LA, Omoto Y, Gustafsson JÅ, Haldosén LA.

Breast Cancer Res. 2011 Apr 14;13(2):R43. doi: 10.1186/bcr2865.

12.

Gefitinib or placebo in combination with tamoxifen in patients with hormone receptor-positive metastatic breast cancer: a randomized phase II study.

Osborne CK, Neven P, Dirix LY, Mackey JR, Robert J, Underhill C, Schiff R, Gutierrez C, Migliaccio I, Anagnostou VK, Rimm DL, Magill P, Sellers M.

Clin Cancer Res. 2011 Mar 1;17(5):1147-59. doi: 10.1158/1078-0432.CCR-10-1869.

13.

Testing for HER2 in Breast Cancer: A Continuing Evolution.

Shah S, Chen B.

Patholog Res Int. 2010 Dec 6;2011:903202. doi: 10.4061/2011/903202.

14.

Androgen receptor overexpression induces tamoxifen resistance in human breast cancer cells.

De Amicis F, Thirugnansampanthan J, Cui Y, Selever J, Beyer A, Parra I, Weigel NL, Herynk MH, Tsimelzon A, Lewis MT, Chamness GC, Hilsenbeck SG, Andò S, Fuqua SA.

Breast Cancer Res Treat. 2010 May;121(1):1-11. doi: 10.1007/s10549-009-0436-8.

15.

Growth factor-induced resistance to tamoxifen is associated with a mutation of estrogen receptor alpha and its phosphorylation at serine 305.

Giordano C, Cui Y, Barone I, Ando S, Mancini MA, Berno V, Fuqua SA.

Breast Cancer Res Treat. 2010 Jan;119(1):71-85. doi: 10.1007/s10549-009-0334-0.

16.

Improvement of sensitivity to tamoxifen in estrogen receptor-positive and Herceptin-resistant breast cancer cells.

Chen B, Wang Y, Kane SE, Chen S.

J Mol Endocrinol. 2008 Nov;41(5):367-77. doi: 10.1677/JME-08-0026.

17.
18.

p27(Kip1) and cyclin E expression and breast cancer survival after treatment with adjuvant chemotherapy.

Porter PL, Barlow WE, Yeh IT, Lin MG, Yuan XP, Donato E, Sledge GW, Shapiro CL, Ingle JN, Haskell CM, Albain KS, Roberts JM, Livingston RB, Hayes DF.

J Natl Cancer Inst. 2006 Dec 6;98(23):1723-31.

19.

p53 protein accumulation predicts resistance to endocrine therapy and decreased post-relapse survival in metastatic breast cancer.

Yamashita H, Toyama T, Nishio M, Ando Y, Hamaguchi M, Zhang Z, Kobayashi S, Fujii Y, Iwase H.

Breast Cancer Res. 2006;8(4):R48.

20.

Long-term prognostic significance of HER-2/neu in untreated node-negative breast cancer depends on the method of testing.

Schmidt M, Lewark B, Kohlschmidt N, Glawatz C, Steiner E, Tanner B, Pilch H, Weikel W, Kölbl H, Lehr HA.

Breast Cancer Res. 2005;7(2):R256-66.

Items per page

Supplemental Content

Support Center